– UK, Burton on Trent – Clinigen Group plc (LON: CLIN), the global pharmaceutical Products and Services company, today announced the appointment to its Board of Elmar Schnee as an Independent Non-Executive Director and Chairman designate and Ian Johnson as a new independent Non-Executive Director and Senior Independent Director both effective from 03 August 2021.
Peter Allen, independent Non-Executive Chairman, will not stand for re-election to the Board at the AGM in November 2021. Peter Allen has served as Chairman since the Group’s IPO in September 2012. It is expected that Elmar Schnee will assume the role of Chairman following the AGM in November 2021.
Ian Nicholson will also step down at the November AGM. Anne Hyland will step down from her position as Senior Independent Director but will remain on Board as Chair of the Audit and Risk Committee.
“We are delighted to welcome Elmar and Ian to Clinigen’s board. Elmar brings with him a huge amount of knowledge and experience across Services and Products businesses and will provide a fresh approach to the Group governance and leadership. Ian has strong UK plc, and sector, experience that will complement our Board.” said CEO, Shaun Chilton.
About Elmar Schnee
Elmar Schnee brings broad experience from the international pharmaceutical industry, having held senior leadership and Board positions across multiple pharmaceutical product and services companies including most recently serving on the Board of Jazz Pharmaceuticals since 2014. Before Jazz Pharmaceuticals and his other Board positions, his career spanned a broad range of senior roles at companies including at Merck KGaA being General Partner and a member of the executive board responsible for the worldwide pharma business and at Merck Serono as CEO and being instrumental in the acquisition of Serono by Merck KGaA, alongside senior global management positions with UCB and Sanofi.
Most recently, Elmar served as a Board member at Jazz Pharmaceuticals from August 2014 until July 2021. Mr. Schnee currently serves as Chairman of the board of two internationally listed companies and is also a director of several privately-held healthcare companies.
Previously, he served as COO and management advisor to MindMaze SA, a neuro-technology company, and has also held several senior managerial positions within the pharmaceutical industry throughout his career.
Elmar Schnee, said: “I am delighted to be joining Clinigen at a time when the Company is playing a significant role in supplying products and services to its customers and patients around the world. Clinigen’s platform has the potential to provide an end-to-end service to pharmaceutical clients – and this part of the business is yet to demonstrate its full potential. I look forward to working with the Board on the next phase of Clinigen’s growth and to unlocking the value-enhancing opportunities.”
Mr. Schnee holds both a bachelor’s degree in marketing and a master’s degree in marketing and general management from the Swiss Institute of Business Administration in Zurich.
About Ian Johnson
Ian Johnson brings significant experience from the healthcare sector, particularly within the UK listed arena, and he currently serves as Executive Chairman of Circassia Group plc.
Ian currently serves as Executive Chairman of Circassia Group and Non-Executive Chairman of Redcentric plc. Mr. Johnson also served as Executive Chairman of Bioquell PLC and Non-Executive Chairman of Quantum Pharma PLC, Cyprotex PLC, and Celsis Group Ltd. Non-Executive Director of Ergomed PLC, and on the Boards of AIM-listed companies Evans Analytical Group and AOI Medical Inc, amongst other listed companies. Mr. Johnson was a founder and CEO of Biotrace International plc, which was an AIM-listed company before its sale to 3M in 2006.
About Clinigen Group
Clinigen Group plc is a global, specialist pharmaceutical services and products platform focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time. The Group operates from sites in North America, Europe, Africa, and the Asia Pacific.
Clinigen has more than 1,000 employees across five continents in 16 countries, with supply and distribution hubs and operational centers of excellence in key long-term growth regions. The Group works with 34 of the top 50 pharmaceutical companies; interacting with over 5,000 hospitals across more than 115 countries.
For more information: https://www.clinigengroup.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
